WUXI BIOLOGICS (CAYMAN) INC.

Analyst Reco. WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Delayed Hong Kong S.E. Other stock markets 07:07:26 29/04/2024 am IST			5-day change	1st Jan Change
13.8 ^HKD	+2.37%		+7.50%	-53.51%

01/04	Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	CI
27/03	WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy	01/03	MT
Hong Kong Stocks Rebound Over Unchanged Fed Rates; Wuxi Up 3%	01/02	MT
Nomura Adjusts Wuxi Biologics’ Price Target to HK$58.44 From HK$82.69, Keeps at Buy	05/12	MT
Nomura Adjusts Wuxi Biologics' Price Target to HK$82.69 From HK$86.68, Keeps at Buy	24/23/24	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$86.86 From HK$94.91, Keeps at Buy	21/23/21	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$94.91 From HK$97.78, Keeps at Buy	14/23/14	MT
New energy shares drag China stocks lower, Fed rate-decision jitters weigh	15/22/15	RE
UBS Adjusts Wuxi Biologics’ Price Target to HK$113.12 From HK$110.67, Keeps at Buy	22/22/22	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$97.78 From HK$95.75, Keeps at Buy	05/22/05	MT
UBS Adjusts Wuxi Biologics (Cayman)'s Price Target to HK$95.75 From HK$100.87, Keeps at Buy	09/22/09	MT
China stocks rise on higher-than-expected borrowing rate cut; foreign inflows surge	20/22/20	RE
UBS Adjusts Wuxi Biologics' Price Target to HK$110.67 From HK$142, Keeps at Buy	29/22/29	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$100.87 From HK$103.28, Keeps at Buy	24/22/24	MT
Nomura Adjusts WuXi Biologics' Price Target to HK$103.28 From HK$149.92, Keeps at Buy	17/22/17	MT
China stocks fall as virus worries, Fed rate hike bets weigh; Hong Kong up	11/22/11	RE
WUXI BIOLOGICS CAYMAN : Nomura Adjusts WuXi Biologics' Price Target to HK$116.8 From HK$213.1, Keeps at Buy	29/21/29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer